Related Experiment Videos
Modulators of multidrug resistance. Preclinical studies
1Stanford University Medical Center, Stanford University, California, USA.
Hematology/Oncology Clinics of North America
|April 1, 1995
Summary
Multidrug resistance (MDR) in cancer is a complex challenge. Research into chemosensitizers offers potential to overcome drug resistance, but clinical application requires further investigation and development of safer, more effective agents.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Multidrug resistance (MDR) is a significant obstacle in cancer chemotherapy.
- P-glycoprotein (P-gp) is implicated in MDR, but its clinical role in humans requires further evidence.
- Resistance modification strategies using chemosensitizers show promise for certain tumors.
Purpose of the Study:
- To explore the potential of chemosensitizers in overcoming MDR in cancer.
- To identify challenges and future directions for clinical application of chemosensitizers.
Main Methods:
- Review of studies on clinical expression of P-gp.
- Analysis of trials involving chemosensitizers with cancer chemotherapy.
- Examination of factors affecting chemosensitizer efficacy and toxicity.
Main Results:
- Evidence for P-gp's role in clinical drug resistance is limited but suggestive.
- Chemosensitizers may modify resistance in some tumors.
- Numerous factors (pharmacokinetics, toxicity, dosing) need in vivo definition for clinical success.
Conclusions:
- Development of more specific, potent, and less toxic chemosensitizers is critical.
- Pharmacologic agents can antagonize experimental drug resistance, offering therapeutic promise.
- Further human studies and rational drug design are needed to establish the clinical importance of MDR and chemosensitizers in cancer treatment.